Back to search results

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia · Mixed Lineage Leukemia Gene Mutation · Refractory AML · AML With Mutated NPM1 · Acute Myeloid Leukemia Recurrent · Acute Myeloid Leukemia, in Relapse · NPM1 Mutation · KMT2Ar · Myeloid Sarcoma · Nucleophosmin 1-mutated Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic - Phoenix, Phoenix, Arizona, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015

  • Moores UC San Diego Cancer Center, La Jolla, California, United States

    Contact: Study coordinator (Krisma Montalvo) · k1montalvo@health.ucsd.edu

  • USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Christine Duran) · duran_c@med.usc.edu · 323-865-0371

  • UCLA - Bowyer Oncology Center, Los Angeles, California, United States

    Contact: Study coordinator (Bruck Habtemariam) · bhabtemariam@mednet.ucla.edu · 310-794-0242

  • UC Irvine Health Chao Family Comprehensive Cancer Center, Orange, California, United States

    Contact: Study coordinator (Research Line) · ucstudy@hs.uci.edu · 877-827-8839

  • University of Colorado, Aurora, Colorado, United States

  • Colorado Blood Cancer Institute, Denver, Colorado, United States

    Contact: Study coordinator (Patient Clinic) · PSLMDLCBCINewClinicPatient@HCAHealthcare.com · 720-754-4800

  • Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut, United States

    Contact: Study coordinator (Farah Fasihuddin) · farah.fasihuddin@yale.edu · 203-737-3472

  • Mayo Clinic Jacksonville, Jacksonville, Florida, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015

  • Emory Healthcare - The Emory Clinic, Atlanta, Georgia, United States

    Contact: Study coordinator (Gigi Stoneback) · gissela.blanco.stoneback@emory.edu

  • Georgia Cancer Center at Augusta University, Augusta, Georgia, United States

    Contact: Study coordinator (Amanda Spires) · amspires@augusta.edu

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States

    Study coordinator · cancer@northwestern.edu · 312-695-9367

  • Loyola University Medical Center, Maywood, Illinois, United States

  • University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

    Contact: Study coordinator (Cena Jones) · cena-jones@uiowa.edu

  • The University of Kansas Medical Center Research Institute, Fairway, Kansas, United States

    Contact: Study coordinator (Thania Medrano) · CTNurseNav@kumc.edu · 913-945-7552

  • University of Kentucky Markey Cancer Center, Louisville, Kentucky, United States

    Contact: Study coordinator (Ashley Walton-Robbins) · Ashley.Walton-Robbins@uky.edu

  • Norton Cancer Institute - St. Matthews, Louisville, Kentucky, United States

    Study coordinator · leukemia-NCIResearch@nortonhealthcare.org · 502-899-3366

  • Ochsner MD Anderson Cancer Center, Jefferson, Louisiana, United States

    Contact: Study coordinator (Amanda Woolery, RN) · amanda.woolery@ochsner.org · 504-842-0275

  • Johns Hopkins School of Medicine, Baltimore, Maryland, United States

    Contact: Study coordinator (I. Gojo) · igojo1@jhmi.edu

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Christine Connelly) · cconnolly1@mgh.harvard.edu · 617-724-1124

  • UMass Chan Medical School, Worcester, Massachusetts, United States

    Study coordinator · Cancer.research@umassmed.edu · 508-856-3216

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Cancer AnswerLine) · CancerAnswerLine@med.umich.edu · 800-865-1125

  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Carmen Rush) · rushc@karmanos.org · 800-527-6266

  • University of Minnesota, Minneapolis, Minnesota, United States

  • Mayo Clinic - Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · 855-776-0015

  • Hackensack University Medical Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Oncology Clinical Research Referral Office) · OncologyResearchReferral@hmhn.org · 551-996-1777

  • Rutgers Cancer Institute, New Brunswick, New Jersey, United States

    Contact: Study coordinator (Anita Trupiano) · ar2069@cinj.rutgers.edu

  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

    Study coordinator · askrpci@roswellpark.org · 877-275-7724

  • New York - Presbyterian / Weill Cornell Medicine, New York, New York, United States

    Contact: Study coordinator (Tania J Curcio) · tjc9003@med.cornell.edu

  • Mount Sinai - Ruttenberg Treatment Center, New York, New York, United States

    Contact: Study coordinator (Tina Czaplinska) · tina.czaplinska@mssm.edu

  • Columbia University Medical Center, New York, New York, United States

    Contact: Study coordinator (Research Nurse Navigator) · cancerclinicaltrials@cumc.columbia.edu · 212-342-5162

  • Stony Brook University Hospital, Stony Brook, New York, United States

    Contact: Study coordinator (Pushpa Talanki) · Pushpa.Talanki@stonybrookmedicine.edu · 631-638-0815

  • Duke Blood Cancer Center, Durham, North Carolina, United States

    Contact: Study coordinator (Quinna Lawson) · quinna.marshburn@duke.edu

  • University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

    Contact: Study coordinator (Sarah Gollwitzer) · Sarah.Gollwitzer@UHhospitals.org

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

    Contact: Study coordinator (Cancer Answer Line) · ADVANIA@ccf.org · 866-223-8100

  • The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

    Contact: Study coordinator (Hanna Cordes) · Hanna.cordes@osumc.edu

  • OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Cynthia Lowery) · Cynthia-Lowery@ouhsc.edu

  • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Jessica Ritter) · Jessica.Ritter@pennmedicine.upenn.edu
    Contact: Study coordinator (Camilla Ludlow) · camila.ludlow@pennmedicine.upenn.edu

  • TriStar Bone Marrow Transplant, Nashville, Tennessee, United States

    Contact: Study coordinator (Ask Sarah) · 844-482-4812

  • Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin, Austin, Texas, United States

    Contact: Study coordinator (Amy Hammack) · amy.hammack@sarahcannon.com

  • UT Southwestern - Simmons Cancer Center, Dallas, Texas, United States

    Contact: Study coordinator (Phase I Team) · HemeTeam@groups.utsouthwestern.edu · 214-648-7097

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Ramya Ganesh) · rganesh@mdanderson.org · 713-792-5640

  • University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

    Contact: Study coordinator (UW Cancer Connect) · clinicaltrials@cancer.wisc.edu · 800-622-8922

  • Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States

    Contact: Study coordinator (Medical College of WI Cancer Center Clinical Trials Office) · cccto@mcw.edu · 414-805-8900
View source on ClinicalTrials.gov(opens in a new tab)